Information Provided By:
Fly News Breaks for April 20, 2015
HTWR
Apr 20, 2015 | 07:26 EDT
Canaccord said the weakness in HeartWare is a buying opportunity citing several encouraging takeaways from their discussions with clinicians during the ISHLT conference and a positive risk/reward scenario. Canaccord reiterated its Buy rating but lowered its price target to $106 from $110 on HeartWare shares.
News For HTWR From the Last 2 Days
There are no results for your query HTWR